ERYTHROMYCIN LACTOBIONATE - Generic Drug Details

What are the generic sources for erythromycin lactobionate and what is the scope of freedom to operate?

Erythromycin lactobionate is the generic ingredient in three branded drugs marketed by Abbott, Hospira, Elkins Sinn, Abraxis Pharm, Baxter Hlthcare, Exela Pharma, Nexus, and Teva Parenteral, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for ERYTHROMYCIN LACTOBIONATE

US Patents:	0
Tradenames:	3
Applicants:	8
NDAs:	10
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	5
Patent Applications:	2,766
What excipients (inactive ingredients) are in ERYTHROMYCIN LACTOBIONATE?	ERYTHROMYCIN LACTOBIONATE excipients list
DailyMed Link:	ERYTHROMYCIN LACTOBIONATE at DailyMed

Recent Clinical Trials for ERYTHROMYCIN LACTOBIONATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prof Dr Jan Tack	N/A
Melinta Therapeutics, Inc.	Phase 2/Phase 3
Cempra Inc	Phase 2/Phase 3

See all ERYTHROMYCIN LACTOBIONATE clinical trials

Pharmacology for ERYTHROMYCIN LACTOBIONATE

Drug Class	Macrolide Antimicrobial Macrolide
Physiological Effect	Decreased Sebaceous Gland Activity

Anatomical Therapeutic Chemical (ATC) Classes for ERYTHROMYCIN LACTOBIONATE

D10AF	Antiinfectives for treatment of acne
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

J01FA	Macrolides
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for ERYTHROMYCIN LACTOBIONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Exela Pharma	ERYTHROMYCIN LACTOBIONATE	erythromycin lactobionate	INJECTABLE;INJECTION	211086-001	Sep 17, 2020		DISCN	No	No
Baxter Hlthcare	ERYTHROMYCIN LACTOBIONATE	erythromycin lactobionate	INJECTABLE;INJECTION	062993-001	May 9, 1989		DISCN	No	No
Hospira	ERYTHROCIN	erythromycin lactobionate	INJECTABLE;INJECTION	050182-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Baxter Hlthcare	ERYTHROMYCIN LACTOBIONATE	erythromycin lactobionate	INJECTABLE;INJECTION	062993-002	May 9, 1989		DISCN	No	No
Teva Parenteral	ERYTHROMYCIN LACTOBIONATE	erythromycin lactobionate	INJECTABLE;INJECTION	063253-001	Jul 30, 1993		DISCN	No	No
Hospira	ERYTHROCIN	erythromycin lactobionate	INJECTABLE;INJECTION	050609-002	Sep 24, 1986		DISCN	Yes	No
Abbott	ERYTHROCIN	erythromycin lactobionate	INJECTABLE;INJECTION	062586-002	Jan 4, 1988		DISCN	No	No

ERYTHROMYCIN LACTOBIONATE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Erythromycin Lactobionate

Introduction to Erythromycin Lactobionate

Erythromycin lactobionate is a soluble salt of erythromycin, a macrolide antibiotic produced by a strain of Streptomyces erythraeus. It is widely used for intravenous administration to treat various bacterial infections[2][5].

Market Overview

The global market for erythromycin lactobionate has been experiencing significant growth driven by several key factors.

Increasing Demand for Antibiotics

The growing prevalence of bacterial infections worldwide, particularly in developing regions where healthcare access is improving, has led to an increased demand for effective antibiotics. This trend is expected to continue, driving the market forward[3].

Advancements in Drug Formulations

Recent innovations in drug formulations, such as advanced extended-release formulations, have enhanced the efficacy and patient compliance of erythromycin lactobionate. These advancements are crucial in improving therapeutic outcomes and reducing dosing frequency[3].

Regulatory Environment

Favorable regulatory environments have also supported the market's expansion. Regulatory bodies are increasingly supportive of new antibiotic therapies, which has encouraged investment and innovation in the sector[3].

Global Market Trends

Geographical Distribution

• North America: This region benefits from a well-established healthcare infrastructure and a high demand for antibiotics, contributing to its leading position in the global market[3].
• Europe: The European market is growing steadily, driven by increasing healthcare expenditures and advancements in pharmaceutical technologies. Collaborative research efforts are also on the rise, aiming to enhance antibiotic therapies[3].
• Asia-Pacific: Rapid urbanization and improving healthcare access in this region are fueling the demand for erythromycin lactobionate. Rising awareness of bacterial infections and the expansion of healthcare facilities further support market growth[3].

Market Size and Growth Rate

The global erythromycin lactobionate market has witnessed significant growth from 2017 to 2022, with a compound annual growth rate (CAGR) that indicates a positive financial trajectory. While exact figures are not provided, the market's expansion is evident from the increasing demand and advancements in the field[4].

Competitive Landscape

Major Industry Players

The market is characterized by the presence of several major industry players. These companies are profiled in detail in market research reports, which include their company profiles, product specifications, capacity, production value, and market shares. This competitive landscape analysis helps in understanding the market dynamics and the strategies employed by key players[1].

Market Competition

The competition in the erythromycin lactobionate market is analyzed by company and by country. This analysis provides insights into the global and Chinese markets, highlighting the market shares, production capacities, and supply and consumption patterns of key manufacturers[1].

Economic Impact and Market Dynamics

Global and Chinese Macroeconomic Environment

The global and Chinese macroeconomic environments play a significant role in shaping the market dynamics of erythromycin lactobionate. Factors such as economic growth, healthcare expenditures, and regulatory policies influence the market's development trends[1].

Upstream and Downstream Analysis

The market dynamics are also influenced by the analysis of upstream raw materials and downstream demand. This analysis helps in understanding the supply chain and the potential bottlenecks or opportunities in the market[1].

Challenges and Opportunities

Development Challenges

Despite the positive growth trajectory, the erythromycin lactobionate market faces challenges such as antibiotic resistance and the need for continuous innovation to stay ahead of emerging bacterial strains. Regulatory hurdles and the need for careful management of side effects, such as QT prolongation and hearing loss, are also significant challenges[2][5].

Development Opportunities

The market offers several opportunities, including the potential for high returns driven by increasing healthcare needs and advancements in drug formulations. Strategic partnerships among pharmaceutical companies to enhance research and development capabilities are also on the rise, presenting lucrative opportunities for businesses involved in the production and distribution of erythromycin lactobionate[3].

Technological Advancements

Biotechnology and Drug Delivery Systems

Advances in biotechnology and drug delivery systems are crucial in the evolution of the erythromycin lactobionate market. These technologies streamline drug development, improve manufacturing efficiency, and enhance therapeutic options. Companies are investing heavily in cutting-edge technologies to stay competitive[3].

Financial Trajectory

Revenue and Growth Projections

The financial trajectory of the erythromycin lactobionate market is positive, with projected growth rates indicating a steady increase in revenue. The market is expected to continue growing, driven by the factors mentioned above, although exact financial projections vary depending on the source[3][4].

Key Takeaways

• The erythromycin lactobionate market is driven by increasing demand for antibiotics, advancements in drug formulations, and favorable regulatory environments.
• The market is characterized by a competitive landscape with major industry players and significant geographical distribution across North America, Europe, and the Asia-Pacific region.
• Economic factors, including global and Chinese macroeconomic environments, influence the market's development trends.
• Despite challenges such as antibiotic resistance, the market offers several opportunities for growth and innovation.
• Technological advancements in biotechnology and drug delivery systems are key drivers of the market's evolution.

FAQs

1. What are the primary drivers of the erythromycin lactobionate market? The primary drivers include increasing healthcare needs, rising incidences of bacterial infections, and advancements in drug formulations.

2. Which regions are leading in the erythromycin lactobionate market? North America, Europe, and the Asia-Pacific region are the leading markets, driven by different factors such as healthcare infrastructure, regulatory environments, and increasing healthcare access.

3. What are the major challenges faced by the erythromycin lactobionate market? The market faces challenges such as antibiotic resistance, regulatory hurdles, and the need for careful management of side effects like QT prolongation and hearing loss.

4. How does the competitive landscape of the erythromycin lactobionate market look? The market is competitive with several major industry players, and the competition is analyzed by company and by country to understand market shares, production capacities, and supply and consumption patterns.

5. What role do technological advancements play in the erythromycin lactobionate market? Technological advancements in biotechnology and drug delivery systems are crucial, as they streamline drug development, improve manufacturing efficiency, and enhance therapeutic options.

Cited Sources

1. Global and Chinese Erythromycin Lactobionate Industry, 2017 - Radiant Insights
2. ErythrocinTM Lactobionate - IV - FDA
3. Pharma and Healthcare Disruptions Erythromycin Estolate Market Trends to Watch - Market Research Intellect
4. Global Erythromycin Lactobionate Market - Research Reports World
5. Erythrocin Lactobionate (Sterile Erythromycin Lactobionate, USP) - FDA